Y

Y-mAbs Therapeutics
D

YMAB

11.620
USD
-0.69
(-5.61%)
مغلق
حجم التداول
5,489
الربح لكل سهم
0
العائد الربحي
0
P/E
-26
حجم السوق
656,959,353
الأخبار المقالات

العنوان: Y/mAbs Therapeutics

القطاع: Healthcare
الصناعة: Biotechnology
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.